CELL-MEDICA
26.9.2013 08:01:51 CEST | Business Wire | Pressemeddelelse
Cell Medica, a leading T cell therapeutics company, today announced the opening of its European commercial manufacturing facility at the Max-Delbrück-Center of Molecular Medicine within the biotechnology park of Campus Berlin-Buch (Germany). This state-of-the-art facility for the GMP production of cell and gene therapies includes approximately 350 m2 clean room space.
Initial manufacturing will focus on Cytovir™ CMV – an innovative treatment which uses the immune cells of a healthy donor to restore viral immunity against Cytomegalovirus infections in patients who are immunocompromized following allogeneic hematopoietic stem cell (bone marrow) transplant. The commercial launch of this product is planned in early 2014 and will confirm Cell Medica’s position as one of the leaders in the development and market delivery of T cell therapeutics – a new paradigm for the treatment of cancer and infections.
Dr. Rainer Knaus, Managing Director of Cell Medica GmbH and Head of the Company’s global manufacturing operations, commented: “This facility has been designed and equipped to provide high quality GMP compliant production of patient-specific cell and gene therapies for distribution across Europe. We are also very fortunate to have attracted highly educated and well-trained personnel who are keen to help shape this new era of cell-based therapeutics”, says Dr. Knaus. “These manufacturing specialists are preparing the facility for the supply of Cytovir CMV in early 2014.”
The facility in Berlin-Buch will also be important for Cell Medica’s planned CITADEL study for the investigation of Cell Medica’s T cell therapy for the treatment of EBV-associated lymphomas. The provision of investigational medicinal products for European study centers will be undertaken following the required regulatory approvals.
The financing of Cell Medica’s investment in the Berlin-Buch facility is supported in part by the Investitionsbank Berlin (IBB), the business development and promotional bank of the Federal Land of Berlin.
Notes to Editors
About Cell Medica
Cell Medica is a cellular therapeutics company engaged in the development, manufacturing and marketing of T cell immunotherapy approaches for the treatment of infections and cancers related to oncogenic viruses. The Company’s lead cell product, Cytovir™ CMV, for the treatment and prevention of cytomegalovirus (CMV) infections in patients following allogeneic bone marrow transplant, is available in the UK and is under development in other territories. Cytovir™ ADV is being developed for the treatment of adenovirus infections in pediatric patients following bone marrow transplantation. Cell Medica is also working with the Center for Cell and Gene Therapy, Baylor College of Medicine, to develop a cancer cellular therapeutic for the treatment of malignancies associated with the oncogenic Epstein Barr Virus.
About T cell immunotherapy
T cell immunotherapy involves harnessing the power and precision of the human immune system to treat disease. Extensive academic research in the field of clinical immunology has provided early evidence that T cells may be used for the treatment of viral infections. Certain cancers are also associated with infection by viruses such as the Epstein-Barr Virus (EBV). Ongoing clinical research at UCL, Baylor College of Medicine and other institutions is exploring how T cell immunotherapy may be used to eliminate malignant cells which express viral antigens.
About Cytovir CMV
Cytovir™ CMV is available on clinician's request (UK only). It is comprised of naturally occurring CMV-specific cytotoxic T lymphocyte cells (T cells) that are directly selected from a seropositive donor. Cytovir CMV is under development by Cell Medica as a novel treatment for cytomegalovirus infections in patients following allogeneic hematopoietic stem cell (bone marrow) transplantation by means of virus-specific immune reconstitution.
In Germany, the competent authority has confirmed that Cytovir CMV can be placed on the market under a manufacturing license.
About cancer cellular therapeutics in development
Cell Medica is developing a formulation of autologous cytotoxic T cell lymphocytes expanded to target EBV tumor-associated antigens. This product is under early phase clinical development as a specific cancer cellular therapeutic for a subset of EBV-associated advanced relapsed, refractory lymphoma.
About IBB
Investitionsbank Berlin (IBB) is the business development and promotional bank of the Federal Land of Berlin. With a wide product spectrum it is active in the areas of business and property promotion. IBB supports small and medium-sized enterprises in Berlin with subsidies, loan products and equity stakes developing targeted solutions for its clients. In doing so it works in close cooperation with all local commercial banks.
Contact:
For more information, please contact:
Gregg Sando, CEO,
Cell
Medica Limited
+44 (0)20 7554 4070
www.cellmedica.co.uk
Information om Business Wire
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
Rubedo’s RLS-1496 Reduces Actinic Keratosis Pre-Cancerous Skin Lesions by 46% at Four Weeks with Minimal Irritation in Preliminary Results of Phase 1b/2a Study28.5.2026 14:30:00 CEST | Press release
RLS-1496 is an investigational, first-in-class, disease-modifying, selective glutathione peroxidase 4 (GPX4) modulator that targets pathologic senescent and other stressed, aging cells that drive chronic, age-dependent diseases, such as AK, and represents a novel drug category — Adaptive SenoTherapeutics In recognition of May as Skin Cancer Awareness Month, Rubedo is calling attention to the myths and facts surrounding AKs — and to the urgent need for a new generation of treatments that are effective without the side-effect burden of today's options Rubedo Life Sciences, Inc. (Rubedo), an AI-driven, clinical-stage biotech focused on selective cellular rejuvenation medicines targeting aging cells, today announced preliminary results from a Phase 1b/2a study of RLS-1496 in patients with actinic keratosis (AK), a common age-related condition resulting in precancerous skin lesions, that is most commonly seen after age 65.1 The open-label multi-center trial, conducted in the United States,
ExaGrid Wins 5 Industry Awards at Network Computing Awards 202628.5.2026 14:00:00 CEST | Press release
ExaGrid named “Company of the Year” for seventh year in a row ExaGrid®, the world’s largest independent backup storage vendor providing Tiered Backup Storage with the most Comprehensive Security and AI-Powered Retention Time-Lock for Ransomware Recovery, today announced that company was honored with five industry awards, including Air-gapped Ransomware Recovery Product of the Year, Bench Tested Product of the Year, Company of the Year, Data Protection Product of the Year, and the Storage Product of the Year during the Network Computing Awards ceremony, held in London on May 21, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260528849813/en/ The ExaGrid team headed to the stage five times throughout the Network Computing Awards ceremony in London to accept awards for ExaGrid Tiered Backup Storage. Photo courtesy of Network Computing Awards. The Network Computing Awards are determined by public vote. The 2026 awards mark
Ardoq Launches AI-First Enterprise Architecture Platform28.5.2026 14:00:00 CEST | Press release
Custom Agents, Omnipresent AI Assistant, and AI Import Builder Automate an Estimated 40% of Routine EA Work; Tenneco Already Achieving 292% ROI on Ardoq AI Ardoq, named a 5x Leader in the Gartner® Magic Quadrant™ for Enterprise Architecture Tools, today launched its AI-first enterprise architecture (EA) platform. The release grounds every Ardoq AI output in customers' live architecture data and introduces a new generation of AI agents capable of automating an estimated 40% of routine EA work. Architects today are being asked to defend decisions that generic AI is generating in seconds. Application rationalization choices. ERP transformation roadmaps. AI governance reviews. The questions land on the architect's desk, but the analysis underneath increasingly comes from AI assistants that do not know the architecture. Generic agents reason on whatever document is in front of them, not on the live relationships between applications, dependencies, capabilities, and risks. Ask a generic LLM
European DataWarehouse Launches DealDox®, a Next-Generation Virtual Data Room Built specifically for the Securitisation Market28.5.2026 14:00:00 CEST | Press release
European DataWarehouse (EDW) announced today the launch of DealDox®, a secure virtual data room uniquely tailored to the needs of the securitisation and structured finance market. Developed in response to long‑standing challenges around transaction data and document management, DealDox provides a single, secure environment where all parties throughout the deal lifecycle can collaborate efficiently while maintaining high standards of security, governance, and regulatory alignment. DealDox enables the centralised management of transaction data and documentation, offering robust security, granular access controls, and clear audit trails. The platform integrates seamlessly with EDW’s existing regulatory reporting ecosystem, supporting smoother workflows from deal preparation through to disclosure and compliance. “As a market infrastructure, our role is to reduce complexity and make processes simpler and more transparent for all participants,” said Dr. Christian Thun, CEO of European DataWa
SLB and Vår Energi Expand Digital Collaboration to Scale Well and Integrated Field Development Planning28.5.2026 13:47:00 CEST | Press release
Agreement supports Vår Energi’s ambition to reduce time to first oil, building on multi-discipline, collaborative well planning workflows that reduce cycle times from months to days Global energy technology company SLB (NYSE: SLB) today announced an expanded collaboration with Vår Energi to scale well planning and integrated field development planning across its Norwegian Continental Shelf operations. With collaborative well planning already reducing cycle times from months to days and integrated field development planning expected to support similar benefits, the expanded deployment is designed to support faster, more consistent decision-making as operators work to sustain production from mature offshore assets while managing increasing development complexity. As part of the expanded collaboration, Vår Energi is deploying the Delfi™ digital platform to connect exploration, subsurface evaluation, well planning, subsea design, field development planning, and production in a cloud-native
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum